Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CLPP | Q16740 | 13/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14309925 | 1.00 | SIGMAR1 (0.37) | SIGMAR1CLPPRIPK1TSHRMEN1 | |
| SCHEMBL14319247 | 0.94 | SIGMAR1 (0.37) | SIGMAR1CLPPTSHRMEN1KMT2A | |
| SCHEMBL17572558 | 0.93 | CLPP (0.39) | CLPPSIRT5ALDH1A1 | |
| SCHEMBL14308273 | 0.90 | KMT2A (0.37) | SIGMAR1CLPPMEN1KMT2ASIRT5 | |
| SCHEMBL14309465 | 0.90 | SIRT5 (0.39) | CLPPTSHRMEN1KMT2ASIRT5 | |
| SCHEMBL13774133 | 0.90 | CLPP (0.45) | CLPP | |
| SCHEMBL13774093 | 0.89 | SIGMAR1 (0.39) | SIGMAR1CLPPRIPK1TSHRMEN1 | |
| SCHEMBL14309966 | 0.89 | SIGMAR1 (0.36) | SIGMAR1CLPPRIPK1TSHRMEN1 | |
| SCHEMBL14309917 | 0.89 | CLPP (0.39) | CLPPMEN1KMT2ASIRT5 | |
| SCHEMBL14319234 | 0.88 | CLPP (0.35) | CLPPSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | SIGMAR1 85/4885CLPP 4872/4885RIPK1 1896/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | SIGMAR1 80/4885CLPP 4874/4885RIPK1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.